Genmab EPS - Earnings per Share 2019-2022 | GMAB

Genmab annual and quarterly earnings per share history from 2019 to 2022. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • Genmab EPS for the quarter ending March 31, 2022 was $0.11, a 60.59% decline year-over-year.
  • Genmab EPS for the twelve months ending March 31, 2022 was $0.56, a 57.31% decline year-over-year.
  • Genmab 2021 annual EPS was $0.73, a 34.45% decline from 2020.
  • Genmab 2020 annual EPS was $1.11, a 116.86% increase from 2019.
  • Genmab 2019 annual EPS was $0.51, a 35.64% increase from 2018.
Genmab Annual EPS
2021 $0.73
2020 $1.11
2019 $0.51
2018 $0.38
Genmab Quarterly EPS
2022-03-31 $0.11
2021-12-31 $0.17
2021-09-30 $0.21
2021-06-30 $0.08
2021-03-31 $0.27
2020-12-31 $0.16
2020-09-30 $0.13
2020-06-30 $0.76
2020-03-31 $0.06
2019-12-31 $0.19
2019-09-30 $0.12
2019-06-30 $0.02
2019-03-31 $0.18
2018-12-31 $2.13
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $19.273B $1.349B
Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.383B 9.82
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.475B 16.53
Biohaven Pharmaceutical Holding (BHVN) United States $9.944B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.681B 0.00
Emergent Biosolutions (EBS) United States $1.444B 6.18
Arcus Biosciences (RCUS) United States $1.389B 35.22
Myovant Sciences (MYOV) United Kingdom $0.879B 0.00
Zymeworks (ZYME) Canada $0.321B 0.00
Gelesis Holdings (GLS) United States $0.173B 0.00
Ambrx Biopharma (AMAM) United States $0.159B 0.00
Enzo Biochem (ENZ) United States $0.114B 23.50
SQZ Biotechnologies (SQZ) United States $0.093B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00